StockData
VivoSim Labs, INC. logo

VivoSim Labs, INC. (VIVS) stock

VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.12−0.00 (-2.91%)

Close on Nov 17, 2026Market cap $383.64KP/E –Yield –

VivoSim Labs r&d expenses

Research and development expenses are spending on new products and technology.

VivoSim Labs's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.32M, down 6.6% year over year. For fiscal 2026 it was $4.19M, down 16.6% from the year before. Over ten years it grew -13.6% a year on average. The highest annual figure on record is $19.55M in fiscal 2017.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$4.19M-16.6%
FY2025Mar 31, 2025$5.03M-8.6%
FY2024Mar 31, 2024$5.50M-38.1%
FY2023Mar 31, 2023$8.89M+167.6%
FY2022Mar 31, 2022$3.32M+201.0%
FY2021Mar 31, 2021$1.10M-79.1%
FY2020Mar 31, 2020$5.28M-64.2%
FY2019Mar 31, 2019$14.75M-17.8%
FY2018Mar 31, 2018$17.96M-8.1%
FY2017Mar 31, 2017$19.55M+8.5%
FY2016Mar 31, 2016$18.01M+39.4%
FY2015Mar 31, 2015$12.92M+276.0%
FY2012Dec 31, 2012$3.44M+142.0%
FY2011Dec 31, 2011$1.42M+18.0%
FY2010Dec 31, 2010$1.20M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$1.13M+13.1%
Q4 FY2026CQ1 2026Mar 31, 2026$1.13M+31.0%
Q3 FY2026CQ4 2025Dec 31, 2025$1.14M-36.0%
Q2 FY2026CQ3 2025Sep 30, 2025$923.00K-6.2%
Q1 FY2026CQ2 2025Jun 30, 2025$1.00M-28.6%
Q4 FY2025CQ1 2025Mar 31, 2025$859.00K-19.2%
Q3 FY2025CQ4 2024Dec 31, 2024$1.78M+24.1%
Q2 FY2025CQ3 2024Sep 30, 2024$984.00K-26.3%
Q1 FY2025CQ2 2024Jun 30, 2024$1.40M-15.8%
Q4 FY2024CQ1 2024Mar 31, 2024$1.06M-80.5%
Q3 FY2024CQ4 2023Dec 31, 2023$1.43M+21.0%
Q2 FY2024CQ3 2023Sep 30, 2023$1.34M+8.4%
Q1 FY2024CQ2 2023Jun 30, 2023$1.67M+63.3%
Q4 FY2023CQ1 2023Mar 31, 2023$5.45M+380.1%
Q3 FY2023CQ4 2022Dec 31, 2022$1.19M+28.0%
Q2 FY2023CQ3 2022Sep 30, 2022$1.23M+81.3%
Q1 FY2023CQ2 2022Jun 30, 2022$1.02M+75.9%
Q4 FY2022CQ1 2022Mar 31, 2022$1.14M+68.6%
Q3 FY2022CQ4 2021Dec 31, 2021$926.00K+130.3%
Q2 FY2022CQ3 2021Sep 30, 2021$679.00K+2325.0%
Q1 FY2022CQ2 2021Jun 30, 2021$580.00K–
Q4 FY2021CQ1 2021Mar 31, 2021$673.00K+364.1%
Q3 FY2021CQ4 2020Dec 31, 2020$402.00K-72.2%
Q2 FY2021CQ3 2020Sep 30, 2020$28.00K-99.3%
Q1 FY2021CQ2 2020Jun 30, 2020$0-100.0%
Q3 FY2020CQ4 2019Dec 31, 2019$145.00K-96.2%
Q2 FY2020CQ3 2019Sep 30, 2019$1.45M-54.7%
Q1 FY2020CQ2 2019Jun 30, 2019$3.82M+13.1%
Q4 FY2019CQ1 2019Mar 31, 2019$4.40M+10.8%
Q3 FY2019CQ4 2018Dec 31, 2018$3.78M-5.6%
Q2 FY2019CQ3 2018Sep 30, 2018$3.19M-35.5%
Q1 FY2019CQ2 2018Jun 30, 2018$3.38M-32.9%
Q4 FY2018CQ1 2018Mar 31, 2018$3.97M-28.2%
Q3 FY2018CQ4 2017Dec 31, 2017$4.01M-20.3%
Q2 FY2018CQ3 2017Sep 30, 2017$4.94M+8.8%
Q1 FY2018CQ2 2017Jun 30, 2017$5.03M–
Q4 FY2017CQ1 2017Mar 31, 2017$5.53M–
Q3 FY2017CQ4 2016Dec 31, 2016$5.02M–
Q2 FY2017CQ3 2016Sep 30, 2016$4.54M–

More VivoSim Labs figures

See a number that looks wrong?